Reassessing the Clinical Value of Momelotinib in Myelofibrosis: An ESMO-MCBS:H-Based Appraisal of SIMPLIFY-1 and MOMENTUM.
- DOI
- 10.1016/j.critrevonc.2026.105627
- Published
- 2026 Sep 26
- Container
- Critical reviews in oncology/hematology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.critrevonc.2026.105627,
title = {Reassessing the Clinical Value of Momelotinib in Myelofibrosis: An ESMO-MCBS:H-Based Appraisal of SIMPLIFY-1 and MOMENTUM.},
author = {Wever SAL and Hoogendoorn M and Klein SK and Van Rijn R and Oortgiesen BE and Ammatuna E},
year = {2026},
journal = {Critical reviews in oncology/hematology},
doi = {10.1016/j.critrevonc.2026.105627},
url = {https://doi.org/10.1016/j.critrevonc.2026.105627}
}RIS
TY - JOUR TI - Reassessing the Clinical Value of Momelotinib in Myelofibrosis: An ESMO-MCBS:H-Based Appraisal of SIMPLIFY-1 and MOMENTUM. AU - Wever SAL AU - Hoogendoorn M AU - Klein SK AU - Van Rijn R AU - Oortgiesen BE AU - Ammatuna E PY - 2026 JO - Critical reviews in oncology/hematology DO - 10.1016/j.critrevonc.2026.105627 UR - https://doi.org/10.1016/j.critrevonc.2026.105627 ER -
APA
SAL, W., M, H., SK, K., R, V. R., BE, O., & E, A. (2026). Reassessing the Clinical Value of Momelotinib in Myelofibrosis: An ESMO-MCBS:H-Based Appraisal of SIMPLIFY-1 and MOMENTUM.. Critical reviews in oncology/hematology. https://doi.org/10.1016/j.critrevonc.2026.105627
Source records
- pubmed · retrieved 2026-09-27T09:11:33.769Z